Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"I'm not too sure management understands this law of the jungle."
I'm not too sure they care?
Was pretty sure that he said it would bounce off $4, could break down to $3.56 and new low.
Does this ever end? Called in my prescription refill last week and went to pick it up today. Upon arrival (Toronto), I was told that the amount owed was $357. I said that I have been on the drug since approval almost one year ago and my insurance provider covers it. After many hours of the run around, I am told this evening that the insurance company now requires a prior authorization form to be filled out by the doctor and sent back to them before they will cover payment.
Absolutely brutal, on top of the 10% haircut AMRN took today.
I show gap support at 6.55 from January and 50 day at 6.59. With any luck, those will show decent support, regardless of JT
Sorry to disappoint you, but never had that issue
$12.50 Raf
With someone acquiring stock yesterday around $4, what is the possibility of offering to acquire AMRN for $8-10, an almost 100% premium, with a cash and stock offering? $6-7 in cash, $2-3 in stock? Not too many of us would be overly happy, but happier than we are now and the stock portion would give us some upside? Just thinking out loud.
HLS has reps visiting docs. My cardiologist happens to be my neighbour so we have talked about Vascepa for the past 6 years. He let me know last November that the HLS rep had visited his office, told him he knew all about it and was waiting for the approval and release by Health Canada. My cardiologist said now that he knows it’s available, he will start to write prescriptions.
Vascepa seems to have a very low profile up here because none of the other docs and cardiologists I know are aware of Vascepa or Reduce It. HLS has a long road ahead of them to educate and promote up here, I am afraid. Hope I’m wrong.
Didn’t ask, but the pharmacy I went to (shopper drug mart, largest in Canada) had never heard of it before and had to check around to find it.
Been 8 years in waiting, but finally got a prescription filled for Vascepa yesterday in Canada. $294 per 120 capsules but insurance was on-board and covered all but the $3.99 dispensing fee.
Waiting to get the first script written in Canada next week. Checked with HLS twice in the last 2 weeks and no information regarding insurance coverage yet. They say they are talking with all the main insurers, but as of this morning my carrier, Sunlife, still shows no coverage. Cost will be $294/30 day supply
BaaBaa,
You're an Aussie?
Harry, Funny that you bring up AF with this. Last one I checked that AF bashed was AMRN and that, unfortunately for the shorts, turned out to be a 7 bagger. Not saying you are right or wrong, but AF and his pal Herpes, definitely have their own agendas.
Dancing,
Don't know about that, I'm in Canada and we have until the end of April, but I would think that the retail selling would be small potatoes in terms of volume
Don't know for sure, but it is quarter end and in my opinion, I would be willing to bet that quite a few of the smaller 'tutes have been locking in their gains since the beginning of the year. They would all have a nice little profit to show for the quarter and they can always buy in later when "something" is going to happen.
Gotta love those ambulance chasers. How come you never hear from them when the shorts get massacred, just the longs?
Well, well, well! I read the 8k and didn't see any omission to the FDA. I guess Blackrock is out of a lot of money because they didn't read the 8k either. Now own about 6% of the stock.
IMO, Baker Bros hold all the cards. Are they a long term shareholder? Will they stick with their holding on a GIA basis? History has proven that they will take a long term view with a stock, but, IMO, only until a buy out occurs. They seem to stick with their chosen stocks for a 10x winner, when possible. They don't seem to stick to small cap stocks on a long term basis for growth. My gut tells me they are still in this stock for a buy out. That may not happen immediately, but to bag another $10, $20 or more from a large BP seems their play. If I saw them sell some or all of their holding, I would think they would not expect a buyout and JT would have said they were going it alone come hell or high water.
JMHO
All we have received is positive results from a trial. We have no FDA approval yet, hence, no movement from the insurance companies and with a new sales force, it will take time to see improvement from them. We now have 40% of the new script market and new scripts are up 32% since just before the September announcement. Not moving as fast as we'd like, but we are up 400%+ in the same time. I'm as greedy as the next guy, but give it a rest.
ONCS filed an 8-k on 12/21/18 stating that they received a delisting notice. All the details are on that.
Nothing seems to bring in the institutional buying that is required to move this stock to another level. Small buying here and there is obviously insignificant against the MM's desire to keep playing the small moves for a penny here and a penny there. Don't know what the conference call will provide, but it must be kept under pretty tight wraps at the moment or it is a non-event.
Sorry, but who was it that didn't like Najaran mentioning their stock? Seems to be reasonably well plugged in to me.
But he happens to be the biggest and brightest candle out there.
Joe Z to haunt us again, however, notice that JT didn't sell any of his exercised options
SRPT is probably not a good comparison because 'tutes own about 94% of the outstanding stock, 'Tutes own less than half that in AMRN. While we will never know the exact level that tute activity got up to in AMRN while it was running, I would be willing to wager that it was close to 65-70%, maybe even higher. Will be interesting to see what the 13F in February discloses, but I would expect that most of the year end window dressing eliminated any significant rise in 'tute ownership.
Where did you find this “give away”? I haven’t seen anything from the company
The one thing I've learned over the years: Stocks can go down on no volume, but they can't go up with no volume.
It would be a tremendous Christmas gift if The Baker Bros would take a position in ONCS. Perhaps the preferred authorization could be afforded to them? This was how AMRN got out of the toilet a few years ago.
$14 for Christmas up from $2.75. Thanks Amrn. Half full or half empty James?
Wonder if the ITC ruling will come any time soon? Just placed my Omegavia epa 500 order and while he was processing the order, we started to chat about the reduce it results and how it must have benefited these guys. He ultimately said that their volume has increased quite dramatically since the results were released. While I can’t procure a prescription in Canada yet, it is the best substitute for me. Having said that, I would much prefer all the Omegavia orders be Vascepa.
Tasty,
Good call on the close today. What say you RAF?
TJ
While the 'tutes were increasing in the second qtr, they unloaded in the third qtr (down 46%). Since the results were released and the stock tanked, the 'tutes may be the ones doing all the buying again at these depressed prices, but we won't know until middle of Feb.
JMO
Take it to the AVXL board, boys, if you want to discuss it
With all the volume that has traded over the last month+, I find it hard to believe that the institutional percentage hasn't gone up. 13F filings are not due to be reported for another 10 days and I would suspect that we will see significantly higher ownership than 43.6%. We know that BB has increased their stake and I'm sure there are others as well. We will see.
not a bad interview with JT, however, he was very careful to not answer the dilution question.
Me,
Really, my comment was just general in nature, but to be a little more specific, Vascepa was approved on July 27 and the Adcom was October 14, 79 days later.
Hey Me,
Like I said, they hired reps prior to the Adcom and then let most of them go
Marz,
Don't forget that we have seen this before. Prior to the Adcom, Amarin went out and actually hired hundreds of reps, only to let most of them go after the negative decision. The good thing about this "preparation" is that they won't actually hire them until the results are in.
DML,
Why don't you call Amarin?
Taking care of the largest generic producer for the next decade is huge, especially with a favourable r-it result. The ITC ruling becomes even more important now, imo, to keep out the DS as well